LM-2417
- Generic Name
- LM-2417
A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours
Phase 1
Not yet recruiting
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: Toripalimab/Tirelizumab
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- LaNova Medicines Limited
- Target Recruit Count
- 320
- Registration Number
- NCT06682780
- Locations
- 🇨🇳
FuDan University Shanghai Cancer Center, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath